Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy

Zachary J Walker1, Beau M Idler1, Lorraine N Davis1

  • 1Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Abstract

Insights

Omacetaxine effectively targets multiple myeloma cells by blocking protein translation, offering a new therapeutic strategy. This drug shows promise alone and in combination with immunomodulatory drugs (IMiDs) for relapsed/refractory disease.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma patients resistant to current therapies face a poor prognosis.
  • Existing treatments like proteasome inhibitors, IMiDs, and daratumumab have limited efficacy in refractory cases.
  • Chimeric antigen receptor T-cell therapies offer only transient benefits.

Purpose of the Study:

  • To investigate omacetaxine, a protein translation inhibitor, as a therapeutic strategy for multiple myeloma.
  • To determine the sensitivity of multiple myeloma cells to omacetaxine.
  • To explore the synergistic effects of omacetaxine with immunomodulatory drugs (IMiDs).

Main Methods:

  • Assessed protein translation levels in 17 primary multiple myeloma samples.
  • Determined omacetaxine sensitivity in 51 primary multiple myeloma samples.
  • Evaluated drug synergy in vitro, ex vivo, and in vivo using cell lines and patient samples.
  • Conducted proteomic analysis to investigate underlying mechanisms.

Main Results:

  • Multiple myeloma cells universally exhibit significantly higher protein translation rates than normal cells.
  • Omacetaxine treatment reduced viable multiple myeloma cells by over 50% ex vivo.
  • High translation rates identified as a biomarker for omacetaxine sensitivity.
  • Omacetaxine demonstrated synergistic effects with IMiDs in vitro.
  • Combination therapy resensitized IMiD-resistant cells and impacted the IRF4/c-MYC pathway.

Conclusions:

  • Protein translation inhibitors represent a promising new drug class for multiple myeloma.
  • Omacetaxine shows potential as a monotherapy or in combination with IMiDs.
  • Clinical trials of omacetaxine are warranted for relapsed/refractory multiple myeloma patients.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K